Resources from the same session
Phase I Clinical development of EGFR E20I inhibitors: Proof of principle studies
Presenter: S.H. Lee, KR
Session: Session 2 – EGFR E20I mutations inhibitor drug development
Resources:
Slides
Webcast
Phase II Clinical development of EGFR E20I inhibitors and emerging evidence from RWD and ongoing trials
Presenter: S. M. Lim, KR
Session: Session 2 – EGFR E20I mutations inhibitor drug development
Resources:
Slides
Webcast
Presentation of clinical cases of patients with advanced NSCLC bearing EGFR E20I mutations: Considerations of access to diagnostics and molecular therapeutics
Presenter: A.M. C. Dingemans, NL
Session: Session 2 – EGFR E20I mutations inhibitor drug development
Resources:
Slides
Webcast